Intravitreal bevacizumab (Avastin) for post-laser photocoagulation anterior segment ischemia in aggressive posterior retinopathy of prematurity.
Sangtam
Tiakumzuk
T
Vinekar
Anand
A
Maheshwar
Bakthavatsalu
B
Dogra
Mangat R
MR
Eong
Kah-Guan Au
KG
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000869:Anterior Eye Segment / Q000098:blood supply*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002648:Child; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007267:Injections; D007511:Ischemia / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D017075:Laser Coagulation / Q000009:adverse effects*; D012178:Retinopathy of Prematurity / Q000601:surgery*; D012720:Severity of Illness Index; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab